Literature DB >> 28929636

Risk factors for the development of antibody-mediated rejection in highly sensitized pediatric kidney transplant recipients.

Irene K Kim1, Jua Choi1, Ashley Vo1, Alexis Kang1, Justin Steggerda1, Sabrina Louie1, Mark Haas2, James Mirocha3, J Louis Cohen1, Helen Pizzo1, Elaine S Kamil1, Stanley C Jordan1, Dechu Puliyanda1.   

Abstract

ABMR remains a significant concern for early graft loss, especially for those who are HS against HLA antigens. We sought to determine the risk factors leading to ABMR in HS pediatric kidney transplant recipients. From January 2009 to December 2015, 16 HS pediatric kidney transplant patients at our center (age range 2-21) were retrospectively reviewed for outcomes and risk factors for ABMR. All HS patients received desensitization with high-dose IVIG/rituximab prior to transplant. Two groups were examined: ABMR+ (n = 7) and ABMR- (n = 9). Patient survival was 100%; however, one patient in the ABMR+ group suffered graft loss from ABMR 16 months post-transplant. ABMR+ patients had higher Class I PRA at the time of transplant (Class I: 73.1 ± 19.1 vs 49.1 ± 28.3, P = .075), although not statistically significant. ABMR+ patients were more likely to have a history of transplant nephrectomy (P = .013). The characteristic that most strongly correlated with ABMR was the DSA-RIS (P = .045), a scoring system used to quantify cumulative intensity of all DSA. In conclusion, DSA, as quantified by the RIS at the time of transplant, should be considered as part of the initial allocation strategy and patients with high RIS monitored closely for ABMR post-transplant.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  ABMR; DSA; desensitization; high sensitization

Mesh:

Substances:

Year:  2017        PMID: 28929636     DOI: 10.1111/petr.13042

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN: 1397-3142


  1 in total

1.  Long term tolerability and clinical outcomes associated with tocilizumab in the treatment of refractory antibody mediated rejection (AMR) in pediatric renal transplant recipients.

Authors:  Meghan Pearl; Patricia L Weng; Lucia Chen; Aditi Dokras; Helen Pizzo; Jonathan Garrison; Carrie Butler; Jennifer Zhang; Elaine F Reed; Irene K Kim; Jua Choi; Mark Haas; Xiaohai Zhang; Ashley Vo; Eileen Tsai Chambers; Robert Ettenger; Stanley Jordan; Dechu Puliyanda
Journal:  Clin Transplant       Date:  2022-06-12       Impact factor: 3.456

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.